Skip to content

Advertisement

  • Letter to the Editor
  • Open Access

C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner

†Contributed equally
Acta Neuropathologica Communications20197:32

https://doi.org/10.1186/s40478-019-0685-7

©  The Author(s). 2019

  • Received: 4 February 2019
  • Accepted: 23 February 2019
  • Published:

Keywords

  • C9orf72
  • Motor deficits
  • C9ALS/FTD
  • Mice

G4C2 hexanucleotide repeat expansions in the first intron of C9ORF72 are the most common cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (collectively, C9ALS/FTD) [4, 6, 11, 14]. Haploinsufficiency (loss-of-function) of C9ORF72 protein is a key proposed disease mechanism which may act in parallel with gain-of-function mechanisms, including toxic RNAs from repeat transcription and dipeptide repeat proteins (DPRs) from repeat-associated non-AUG (RAN) translation [5, 9, 17]. However, the effect of C9orf72 deficiency in the background of gain-of-function has not been examined in vivo. Neither heterozygous nor homozygous knockout (KO) of C9orf72 in neurons leads to motor deficits in mice [8]. Recently, gain-of-function mouse models were generated using a C9ORF72 bacterial artificial chromosome (BAC) from C9ALS/FTD patient DNA under the control of the endogenous regulatory elements. Interestingly, three out of four of these C9-BAC transgenic mice did not develop motor behavior deficits, even at advanced ages [7, 12, 13]. Since these C9-BAC mouse models contain elevated C9orf72 proteins from the endogenous mouse gene, we hypothesized that C9orf72 provides neuroprotective effects against motor deficits in C9-BAC mice.

To test this hypothesis and investigate the in vivo significance of C9orf72 haploinsufficiency, we crossed C9orf72+/− mice with C9-BAC mice and examined the consequences of C9orf72 protein dose reduction (loss-of-function) in the background of C9-BAC (gain-of-function). We found that C9orf72 loss and haploinsufficiency exacerbate motor behavior deficits in a dose-dependent manner, and this occurs early in the course of pathogenesis (4 months of age). Among the four published C9-BAC mouse models, we selected the one with motor deficits (we refer to this C9orf72 BACTg/+ model as the C9-BAC line here) [10]. To reduce C9orf72 protein levels at different doses, we crossed C9orf72+/− and C9-BAC mice for two generations. We isolated proteins from brain tissues and confirmed the expected C9orf72 protein dose reduction (Fig. 1a, Additional file 1: Figure S1A). The unchanged protein level of Atg101, which is associated with the C9orf72/Smcr8 complex based on our previous study [16], suggests the specificity of C9orf72 reduction (Fig. 1a, Additional file 1: Figure S1A).
Fig. 1
Fig. 1

C9orf72 dose is critical for motor deficits in C9ALS/FTD mouse models. a Western blot analysis of C9orf72 and Atg101 protein levels in 2-month-old mouse cortex. β-Actin serves as the loading control. b, c Accelerating rotarod test was performed on 4-month-old mice to examine the latency to fall of females (b) and males (c). C9orf72 deficiency decreases the latency to fall of C9-BAC female mice in a dose-dependent manner. d A 4-consecutive-day rotarod assay reveals defective motor learning in C9orf72+/−;C9-BAC and C9orf72−/−;C9-BAC female mice in comparison to WT. e, f Grip strength test was performed to measure front paw strength in 4-month-old females (e) and males (f). All data are presented as mean ± SEM using numbers (n) of mice as indicated. Statistical analyses were performed with one-way ANOVA with Bonferroni’s post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001, N.s represents no significant difference detected in measurement of 2d, 3d, or 4d in comparison to that of 1d)

To study effects of C9orf72 deficiency on the motor behaviors of C9-BAC mice, we monitored a cohort of mice [20 WT (10 females + 10 males), 18 C9-BAC (11 females + 7 males), 26 C9orf72+/−;C9-BAC (14 females + 12 males), and 19 C9orf72−/−;C9-BAC (10 females + 9 males)]. We excluded C9orf72+/− and C9orf72−/− mice for the following reasons: C9orf72 heterozygous and homozygous KO mice exhibited no neurodegeneration and motor deficits based on previous studies [8]; complete deletion of C9orf72, which does not occur in C9ALS/FTD patients, led to autoimmune disorders and reduced survival in mice [1], which may complicate large-scale behavior and survival studies. We found that there were no significant differences among the four tested groups in their survival around 4 months, when behaviors were assessed. They also exhibited similar body weights, taking the sex of the mice into account (Additional file 1: Figure S1B-1C). To examine their general anxiety levels, we performed an open field test [3]. C9-BAC mice with different C9orf72 levels behaved similarly in total distance traveled, distance traveled in the center, and time spent in the center (Additional file 1: Figure S1E-1G).

We next examined their motor coordination and balance using an accelerating (4–40 rpm in 5 min) rotarod test. Mice were given five trials per day, with an inter-trial interval of 20 min, for 4 consecutive days. A C9orf72 dose-dependent decrease in latency to fall was detected in C9-BAC female mice (Fig. 1b), and in C9-BAC male mice on day 4 of the rotarod assay (Fig. 1c). These results suggest that motor coordination is sensitive to C9orf72 protein levels in C9-BAC mice. We further analyzed motor learning in female mice. WT mice exhibited an increase in latency to fall over the course of 4 consecutive days, indicating active motor learning (Fig. 1d). Latency to fall of C9-BAC mice was increased on day 2 but dropped on days 3 and 4 (Fig. 1d). Importantly, there was no increase in latency to fall from day 1 to day 4 in C9orf72+/−;C9-BAC and C9orf72−/−;C9-BAC animals (Fig. 1d). These results suggest that C9orf72 deficiency impaired motor coordination and motor learning of C9-BAC mice in a dose-dependent manner.

To examine motor strength, we measured forearm grip strength and found that it was significantly reduced in both male and female C9orf72−/−;C9BAC animals compared to other genotypes (Fig. 1e, f). Lastly, we measured the maximal speed at which each animal fell from the rotarod device. Results showed that C9orf72 deficiency, in a dose-dependent manner, decreased the maximum speed at which C9-BAC mice fell (Additional file 1: Figure S1H, S1I), which is consistent with the data on their latency to fall.

The rotarod assay revealed more evident motor impairment in female mice than in male mice. This could be due to toxic gain-of-function since C9-BAC female mice exhibited earlier and more pronounced abnormalities than male mice [10]. It will be important to examine using similar cohorts of mice whether motor neurons (MNs) degenerate or reduce in number in a C9orf72 dose-dependent manner and whether these deficits correlate with the observed motor behavior deficits. Future studies should also investigate whether C9orf72 exhibits dose-dependent effects in the three other C9-BAC mouse models [7, 12, 13]. It will be informative to examine the effects of C9orf72 deficiency in the background of adeno-associated virus (AAV)-mediated G4C2 repeat expression [2]. Our study indicates that C9orf72 haploinsufficiency contributes to disease onset in a mouse model by exacerbating the pathogenic effects of RNA/DPR-mediated neurotoxicity. Together with a recent report on patient iPSC-derived MNs [15], this study suggests indeed that we should focus more on the combination of loss- and toxic gain-of-function. Together, for the first time, our mouse genetic studies showed that C9orf72 loss or haploinsufficiency in a gain-of-function mouse model of C9ALS/FTD exacerbate motor behavior deficits in a dose-dependent manner, demonstrating the importance of C9orf72 haploinsufficiency in vivo.

Notes

Declarations

Acknowledgments

We thank Chen laboratory colleagues for stimulating discussions. We are grateful for Bridget Samuels’s critical reading of the manuscript. Chen laboratory is supported by funds from the Associate Dean of Research Fund from the Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry at the University of Southern California, and grants R01NS097231 (J.C.) and R01NS096176 (J.C.) from the National Institute of Health.

Authors’ contributions

QS, QC, CL performed all behavior studies and statitical analyses. MY and WZ helped with the manuscript writing. J-FC designed and interpreted the experiments and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Center for Craniofacial Molecular Biology, University of Southern California (USC), Los Angeles, CA 90033, USA

References

  1. Burberry A, Suzuki N, Wang J-Y, Moccia R, Mordes DA, Stewart MH et al (2016) Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 8:347ra93–347ra93View ArticleGoogle Scholar
  2. Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang Y-J, Castanedes-Casey M et al (2015) Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 348:1151–1154View ArticleGoogle Scholar
  3. Crawley JN (1999) Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835:18–26View ArticleGoogle Scholar
  4. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 72:245–256View ArticleGoogle Scholar
  5. Gao F-B, Almeida S, Lopez-Gonzalez R (2017) Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J EMBO Press 36:2931–2950View ArticleGoogle Scholar
  6. Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G et al (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11:54–65View ArticleGoogle Scholar
  7. Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A et al (2016) Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 90:535–550View ArticleGoogle Scholar
  8. Koppers M, Blokhuis AM, Westeneng H-J, Terpstra ML, Zundel CAC, Vieira de Sá R et al (2015) C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol 78:426–438View ArticleGoogle Scholar
  9. Ling S-C, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 79:416–438View ArticleGoogle Scholar
  10. Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR et al (2016) C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron. 90:521–534View ArticleGoogle Scholar
  11. Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S et al (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11:323–330View ArticleGoogle Scholar
  12. O’Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A et al (2015) C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 88:892–901View ArticleGoogle Scholar
  13. Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J et al (2015) Human C9ORF72 Hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 88:902–909View ArticleGoogle Scholar
  14. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 72:257–268View ArticleGoogle Scholar
  15. Shi Y, Lin S, Staats KA, Li Y, Chang W-H, Hung S-T et al (2018) Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med Nature Publishing Group 24:313–325View ArticleGoogle Scholar
  16. Yang M, Liang C, Swaminathan K, Herrlinger S, Lai F, Shiekhattar R et al (2016) A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Sci Adv American Association for the Advancement of Science 2:e1601167–e1601167Google Scholar
  17. Zu T, Pattamatta A, LPW R (2018) Repeat-Associated Non-ATG Translation in Neurological Diseases. Cold Spring Harb Perspect Biol. Cold Spring Harbor Lab 10:a033019View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us